# NCT05104736 (NCT05104736)

> PT-112 in Subjects With Thymoma and Thymic Carcinoma

No report yet. It can be ordered.

- Drugs tested: PT-112
- Indication: thymoma and thymic carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05104736
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Thymic Epithelial Tumor; Recurrent Thymoma; Thymic Cancer
- Interventions: PT-112
- Enrollment: 53
- Primary outcome: overall response rate (ORR)

## Indexed commentary on NCT05104736 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct05104736